35
Participants
Start Date
October 31, 2018
Primary Completion Date
October 1, 2025
Study Completion Date
October 1, 2026
Talazoparib
Given PO
Temozolomide
Given PO
Orlando Health, Inc. d/b/a Orlando Health UF Health Center, Orlando
Ft. Wayne Medical Oncology and Hematology, Inc., Fort Wayne
Cancer Center of Kansas, Wichita
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles
St. Joseph Heritage Healthcare, Fullerton
CBCC Global Research, Inc. at Comprehensive Blood and Cancer Center, Bakersfield
Collaborators (1)
Translational Research in Oncology
OTHER
Pfizer
INDUSTRY
Jonsson Comprehensive Cancer Center
OTHER